The 5th International Workshop on Genotoxicity Testing (IWGT) was held on August 17-19, 2009, at Biozentrum of the University of Basel, Switzerland, prior to the 2009 International Conference on Environmental Mutagens (ICEM), Florence, Italy. In this workshop, approximately 200 participants from government, industry and academia, mainly from the USA, EU, Canada and Japan, discussed the following six topics: 1) suitable maximum concentrations for tests with mammalian cells (this group was divided into two subgroups: 1a) in vitro chromosome aberrations and micronuclei, and 1b) mammalian cell gene mutations); 2) photogenotoxicity testing requirements; 3) in vitro test approaches with better predictivity; 4) improvement of in vivo genotoxicity assessment, i.e., the link to standard toxicity testing; 5) use of historical control data in the interpretation of positive results; and 6) suitable follow-up risk assessment testing for in vivo positive results.
Dr. Toshio Kasamatsu (Kao Co.) and I were invited to the group on topic 3,``In Vitro Test Approaches with Better Predictivity''. Over the course of seven presentations within the group, we discussed new test methods based on the following background. In sharp contrast with other groups, a new subgroup (led by Stefan Pfuhler, Procter & Gamble: P&G) was convened to develop consensus recommendations for choosing a better test systems to improve the predictivity of in vitro tests. This group reviewed current studies investigating whether certain cell types were more susceptible to give irrelevant positive results in vitro.
The background for the discussion is as follows: 1) The high rate of false positive results in the current battery of in vitro tests-as high as 80z when mammalian cell assays are combined (i.e., chromosome aberration assay and mouse lymphoma assay) (1); 2) Seventh Amendment to EU Cosmetics Directive:
Marketing and testing ban on ingredients tested in vivo, which came into force March 2009 (2); 3) REACH (Registration, Evaluation, Authorization and Restriction of Chemical) issue. The REACH Regulation gives greater responsibility to industry to manage the risks from chemicals and to provide safety information on the substances (3). Particularly, the European testing ban resulting from the Seventh Amendment to the EU Cosmetics Directive may result in valuable compounds being unnecessarily discarded from European cosmetic markets. In theˆeld of mutagenicity/genotoxicity, validated alternative methods are available, and in vivo studies were prohibited in EU territory after March 11, 2009 (2) . In spite of the high rate of false positive results in the current battery of in vitro tests, the Scientiˆc Committee on Consumer Safety (SCCS) (4), a European regulatory agency, recommends a battery of three in vitro assays: a bacterial reverse mutation test; an in vitro mammalian cell gene mutation test; and either an in vitro micronucleus test or in vitro mammalian chromosome aberration test. False positive results may be due to experimental conditions that have no relevance to in vivo situations. It is hard to conˆrm or deny the genotoxicity potential of candidate cosmetic ingredients based on results of the current in vitro tests. Therefore, we hope to develop promising new approaches for in vitro testing that can be used in place of in vivo studies to reduce the high incidence of false positive results of existing in vitro testing.
First, the group addressed the following questions: Choice of cell line: IIVS) presented``A novel micronucleus assay conducted in reconstructed human skin''; micronucleus data generated in 3-D skins (COLI-PA 3-D skin project); Gladys Ou áedraogo (L'Oreal) presented``The comet assay on 3-D skins (COLIPA 3-D skin project)''; Hajime Kojima presented``Proposal of protocol for comet assay using a three-dimensional epidermal model''. From these presentations, we reached a consensus, which were re‰ected in the following statements in thê nal IWGT comments: 1. Data were presented indicating that p53-compromised rodent cell lines over-estimate genotoxic potential in the micronucleus test. Therefore, IWGT suggests in vitro micronucleus or chromosome aberration assay using p53-competent cells. The data presented at the IWGT from the OECD MNvit test showed that all cell types correctly identify clastogens and aneugens. However, the data of the compounds that gave false results in the MNvit test suggested that there was a great diversity of the responses of the various cell types. The group agreed, based on the similarity of MNvit and chromosome aberration assays, that the diversity would also be observed in the chromosome aberration assay. HepaRG is a promising model, in that the cells appear to have better phase I and II metabolizing potential than the other cell lines. However, further evaluation is required in order to conˆrm the value of this model for genotoxicity testing.
2. It has been demonstrated that cell line stability and source can aŠect the outcome of genotoxicity assays. Therefore, IWGT recommends adhering to good cell culture practices, characterizing all new cells, checking regularly for drift, and working from low-passage stocks. It would be useful to compile a common genotoxicity cell bank with fully characterized stocks of all cells. 3. Genotoxicity testing in 3-D skins (micronucleus test and comet assay) is a promising new in vitro test for chemicals applied to the skin. The advantage of the model is that it resembles the properties of human skin (barrier function, metabolism), and that the route of exposure is relevant for dermally applied chemicals (e.g., cosmetics). The data presented show that the micronucleus assay by 3-D skin is further advanced; furthermore, inter-and intralab reproducibility has been demonstrated. IWGT agreed that the comet assay should be further evaluated. The comet assay is seen as a valuable addition, as it is not dependent on cell proliferation and covers a wider spectrum of DNA damage. The metabolic capacity needs to be further evaluated (this work is ongoing). It would be valuable to capture the kinetics of penetration and toxicity in order to establish the ideal sampling time(s) for the comet assay. Recommendations on the use of appropriate vehicles should be established. It was agreed that 3-D skin, once validated, will be useful for following up on positive results from standard in vitro assays for dermally applied chemicals. The applicability domain will be established once the validation is completed.
Considering the EU situation and the international expansion of animal welfare laws, we must avoid progressively adopting in vivo genotoxicity testing. Therefore, I think that the consensus in this group was made``according to script'', at least with regard to European colleagues. Against European drastic transformation, my concern on the safety evaluation is that the trend may push out in vivo testing in the cosmeticˆeld. We must send out a warning about the current trend to avoid all in vivo tests and emphasize importance of reevaluating cell lines and validating studies on new approaches to testing in vitro. I think further discussion is needed to established well-balanced in vitro and in vivo tests for evaluation of genotoxic risk of chemicals to human.
